TY - JOUR AU - Niegisch, Günter PY - 2019 TI - Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy? JF - Translational Andrology and Urology; Vol 8, Supplement 3 (July 16, 2019): Translational Andrology and Urology Y2 - 2019 KW - N2 - There is an ongoing debate whether every eligible patient suffering from muscle-invasive bladder cancer should undergo cisplatin-based neoadjuvant chemotherapy (NAC) before definitive treatment by radical cystectomy. Supporters of this approach refer to level 1 evidence given by high quality meta-analyses indicating a survival benefit of at least 5% improvement in 5-year overall survival by NAC ( Table 1 ) (1-5). Given that most patients relapsing from bladder cancer will present with distant metastases rather than local recurrence (6,7), NAC is thought to tackle micrometastatic disease. UR - https://tau.amegroups.org/article/view/25375